Medline Inc. (MDLN) Reports Q2 EPS of $0.50

Medline Inc. (NASDAQ: MDLN) reported Q2 EPS of $0.50, versus $0.83 reported last year. Revenue for the quarter came in at $7.7 billion, versus $6.89 billion reported last year.

2026 Guidance
The Company is updating its full year 2026 outlook for Organic Sales2 growth to 9.0% to 10.0%, compared to its previous outlook of 8.5% to 9.5%, reflecting strong existing and new customer demand. The Company updated its Adjusted EBITDA2 outlook to $3.3 billion to $3.4 billion, compared to its previous outlook of $3.5 to $3.6 billion, primarily reflecting higher than expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness. The Organic Sales2 reflects IEEPA tariff customer repayments and the Adjusted EBITDA2 outlook does not reflect the benefit of IEEPA tariff refunds.

For earnings history and earnings-related data on Medline Inc. (MDLN) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Myriad Uranium completes acquisition of Rush Rare Metals
• Nuvectis Pharma (NVCT) files $200M mixed shelf